Hansa Biopharma Publishes the Annual Report for 2018

LUND, Sweden, April 15, 2019 /PRNewswire/ -- Hansa Biopharma AB (NASDAQ Stockholm: HNSA), the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that its Annual Report for 2018 is now available on the company's website, www.hansabiopharma.com

This is information that Hansa Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below at 08:00am CET on April 15, 2019.

About Hansa Biopharma

Hansa Biopharma AB (NASDAQ Stockholm: HNSA) is harnessing its proprietary immunomodulatory enzyme technology platform to develop treatments for rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection and cancer. The Company's lead product, IDEFIRIX (imlifidase), is a unique antibody-degrading enzyme in late-stage clinical development to enable kidney transplantation in highly sensitized patients, with additional clinical studies in acute autoimmune indications. Hansa's research and development program is advancing the next generation of the Company's technology to develop novel IgG-cleaving enzymes with lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases and oncology. Hansa Biopharma is based in Lund, Sweden.

For further information, please contact:

Company:
Emanuel Björne, Vice President Business Development and Investor Relations
Hansa Biopharma AB (Publ) Mobile: +46-70-717-5477
E-mail: emanuel.bjorne@hansabiopharma.com

http://hansabiopharma.com

Swedish Investor and Media Relations:
Cord Communications Mikael Widell
+46-70-311-99-60

U.K. Investor and Media Relations:
FTI Consulting
Simon Conway / Natalie Garland-Collins
+44(0)20-3727-1000

U.S. Investor and Media Relations:
Argot Partners
Stephanie Marks / David Rosen (media)
+1-212-600-1902

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/hansa-biopharma-ab/r/hansa-biopharma-publishes-the-annual-report-for-2018,c2789121

The following files are available for download:

View original content:http://www.prnewswire.com/news-releases/hansa-biopharma-publishes-the-annual-report-for-2018-300831841.html

SOURCE Hansa Biopharma AB